CLDX Celldex Therapeutics

Celldex Therapeutics Announces Multiple Upcoming Presentations of Barzolvolimab Data at GA²LEN Global Urticaria Forum (GUF) 2022

Celldex Therapeutics Announces Multiple Upcoming Presentations of Barzolvolimab Data at GA²LEN Global Urticaria Forum (GUF) 2022

- Includes oral presentation for 1.5 mg/kg cold urticaria cohort -

- Company to host webcast conference call on Tuesday, December 6 at 8:00 am ET -

HAMPTON, N.J., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that multiple presentations from the barzolvolimab development program will be presented at the 6th GA2LEN Global Urticaria Forum (GUF) being held December 7-8 in Berlin, Germany. Abstracts will be available on the meeting website on December 6th.

Presentations at GUF 2022 are outlined below and include new data from both the Phase 1b 1.5 mg/kg cohort conducted in cold urticaria and long term follow data from the Phase 1b 3.0 mg/kg cohorts conducted in cold urticaria and symptomatic dermographism. The chronic spontaneous urticaria (CSU) and wound healing presentations are Encore presentations and do not include new data.



WEDNESDAY, December 7, 2022

  • Oral: “Cold urticaria patients achieve complete response with 1.5 mg/kg barzolvolimab” - Session III: Urticaria treatments and predictors of response | 18:07-18:16 CET

THURSDAY, December 8, 2022

  • Poster: “Barzolvolimab-induced response and mast cell suppression are durable and linked” | 10:00 to 11:10 CET
  • ENCORE Oral: “Multi-dosed barzolvolimab is effective in chronic spontaneous urticaria” - Session IV: Treatment of urticaria | 09:05-09:14 CET
  • ENCORE Poster: Mast cell reduction does not impair human cutaneous wound healing

Webcast and Conference Call

The Company will host a conference call/webcast to discuss the data at 8:00 a.m. ET on Tuesday, December 6. The event will be webcast live and can be accessed by going to the "Events & Presentations" page under the "Investors & Media” section of the Celldex Therapeutics website at .

About Celldex Therapeutics, Inc.

Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer. Visit .

Company Contact

Sarah Cavanaugh

Senior Vice President, Corporate Affairs & Administration

(508) 864-8337

Patrick Till

Meru Advisors

(484) 788-8560



EN
02/12/2022

Underlying

CLDXCelldex Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Celldex Therapeutics

 PRESS RELEASE
Free
CLDX Celldex Therape...

Celldex to Present at Upcoming Investor Conferences

Celldex to Present at Upcoming Investor Conferences HAMPTON, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in fireside chats at the following upcoming investor conferences: Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11 at 3:30 pm ETTD Cowen 46th Annual Health Care Conference on Wednesday, March 4 at 9:10 am ETLeerink Global Healthcare Conference on Tuesday, March 10 at 3:40 pm ET Live webcasts of the presentations will be available on the "" page of the "Investors" section of the Celldex websit...

February 9, 2026 1 EN
 PRESS RELEASE
Free
CLDX Celldex Therape...

Celldex Initiates Global Registrational Phase 3 Program of Barzolvolim...

Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism No advanced therapies approved to treat ColdU and SD—diseases of misery that dramatically impact all aspects of patient lifeBarzolvolimab is the only drug in development to demonstrate clinical benefit in patients in ColdU and SD in a large, randomized, placebo-controlled study--all primary and secondary endpoints met with high statistical significance at 12 weeks and sustained through end of treatment period (20 weeks) in Phase 2 studyInitiation of EMBARQ-ColdU and SD ma...

December 9, 2025 1 EN
 PRESS RELEASE
Free
CLDX Celldex Therape...

Celldex Reports Third Quarter 2025 Financial Results and Provides Corp...

Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate Update Strong execution and continued progress across pipeline Positive Phase 2 barzolvolimab data in Chronic Spontaneous Urticaria (CSU) demonstrating rapid, profound improvement in UCT7 scores with sustained disease control post treatment and strong efficacy regardless of baseline IgE levels Positive Phase 2 barzolvolimab data in Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) demonstrating sustained efficacy and favorable safety profile at 20 weeks; first large, randomized, placebo-controlled study to ...

November 10, 2025 1 EN
 PRESS RELEASE
Free
CLDX Celldex Therape...

Celldex Announces Appointment of Teri Lawver as Chief Commercial Offic...

Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer HAMPTON, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ: CLDX) today announced the appointment of Teri Lawver as Senior Vice President, Chief Commercial Officer. Ms. Lawver is an accomplished global healthcare executive with 30 years of strategic, commercial launch and operating P&L leadership across the biopharmaceutical, medical device and consumer health technology sectors. Ms. Lawver succeeds Richard Wright, who will retire from Celldex following more than a decade of dedicated leadership and service. “...

November 10, 2025 1 EN
 PRESS RELEASE
Free
CLDX Celldex Therape...

Celldex to Present at Upcoming Investor Conferences

Celldex to Present at Upcoming Investor Conferences HAMPTON, N.J., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in fireside chats at the following upcoming investor conferences: Guggenheim 2nd Annual Healthcare Innovation Conference on Tuesday, November 11 at 10:00 am ETTD Cowen Immunology & Inflammation Summit on Thursday, November 13 at 9:30 am ET8th Annual Evercore Healthcare Conference on Tuesday, December 2 at 3:00 pm ET Live webcasts of the presentations will be available on the "" page of the "Investors" section of t...

November 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch